In vitro studies have shown that gastroenteropancreatic tumors, with the exception of insulinomas, have a high density of somatostatin receptors and can be imaged in vivo using somatostatin receptor scintigraphy (SRS) [2, 3] . These studies generally show that selective angiography and MRI are the most sensitive
INTRODUCTION
Imaging studies are essential for planning an appropriate strategy in the management of gastrointestinal neuroendocrine tumors, carcinoid tumors and pancreatic endocrine tumors (PETs)b [1] [2] [3] . A number of conventional imaging methods such as ultrasound, computed tomographic scanning (CT), magnetic resonance imaging (MRI) and selective angiography [1, 2, [4] [5] [6] , and for functional neuroendocrine tumors, functional localization methods have been recommended, such as portal venous sampling for hormonal gradients and selective intra-arterial provocative tests with hepatic venous sampling for hormone concentrations [7] [8] [9] [10] . For carcinoid tumors, either conventional imaging methods, gastrointestinal barium studies and/or endoscopy are generally used [2, 3] . These studies generally show that selective angiography and MRI are the most sensitive a To whom all correspondence should be addressed: Robert T. Jensen [1, 6, 12] .
Recently, two newer localization methods using somatostatin receptor scintigraphy (SRS) or endoscopic ultrasound (EUS) are increasingly recommended. Several recent studies reported that SRS is superior to some conventional imaging studies in localizing gastrointestinal neuroendocrine tumors [13] [14] [15] [16] [17] [18] [19] [20] [21] . However, the information on SRS sensitivity compared with that of other imaging techniques is limited in most studies in various ways. Until recently the number of patients studied in the different series was small. Only a few studies compared SRS systematically with that of most sensitive conventional imaging methods, particularly selective angiography and MRI using STIR (short-time inversion-recovery sequences) [1, 6, 11] . The assessment of tumor detection was often on a lesion-by-lesion basis, and therefore, it was difficult to relate it to a given patient's management. Finally, many studies did not assess the sensitivity of SRS relative to other methods in different clinical situations such as whether localization methods were being used to identify a primary tumor or whether the localization studies were being performed to identify metastatic disease. This latter point is particularly important because some localization methods are better for localizing primary tumors, whereas other are used primarily to localize metastatic disease in the liver [1, 4, 11, [22] [23] [24] . Recently, endoscopic ultrasound has been increasingly used for localization of PETs and reported to be more sensitive than conventional imaging methods in detecting PETs, with its sensitivity reaching 94 percent in some series [23, [25] [26] [27] [28] [29] [30] [31] [32] [33] . At present, only a few studies have compared the relative sensitivity of endoscopic ultrasound to the SRS in localizing PETs [23, 27, 28] , and the experience with nonfunctional or carcinoid tumor is even more limited. At present the relative roles of EUS and SRS in localization of PETs is unclear and controversial.
Recently, we have begun prospective studies to address both the sensitivity of SRS compared to conventional imaging studies and the sensitivity of endoscopic ultrasound compared to other tumor localization modalities in patients with gastrinomas. The first study is now completed and in this paper we will review the methods, results, and implications of this study. The NIH endoscopic ultrasound study is just beginning. Thus, in the latter part of this paper, the recent data from other centers on the use of endoscopic ultrasound to localize gastrointestinal neuroendocrine tumors will be reviewed briefly.
NIH STUDY ON THE COMPARATIVE SENSITIVITY OF SRS AND CONVENTIONAL IMAGING STUDIES IN LOCALIZING GASTRINOMAS
In this study we prospectively compare the ability of SRS with that of other conventional imaging methods including ultrasound, CT, MRI and selective angiography to localize primary and metastatic gastrinoma in 80 consecutive patients with the ZollingerEllison syndrome [34] .
Methods
All patients underwent SRS, CT, ultrasound, bone scanning, and MRI including TI-weighted spin-echo sequences and STIR sequences as described previously [1, 11, 24, 35] . Selective angiography was performed with selective injection of splenic, superior mesenteric, gastroduodenal and hepatic arteries as described elsewhere [1, 9, 10] 24 hours. Results of SRS were obtained while the nuclear medicine radiologist was blinded to the results of the conventional imaging studies. All imaging studies were evaluated in two separate aspects: whether a possible primary or extrahepatic tumor was localized and whether hepatic metastases were found. All patients with suspected metastatic disease in the liver underwent percutaneous biopsy. The results are expressed as percentage of patients in whom any extrahepatic or hepatic tumor was localized. Each patient was counted only once (Table 1) . Results CT, MRI or angiography identified extrahepatic tumors in 28 percent to 31 percent and ultrasound detected extrahepatic tumors in 9 percent of patients ( Table 1) . Extrahepatic tumors were detected in 58 percent (46/80) of patients with SRS only, which was significantly more sensitive (p < .001) ( Table 1 ) than any conventional imaging methods alone, and it was equally sensitive to all conventional imaging methods combined. Figure 1 , bottom, is an example of SRS localizing an extrahepatic gastrinoma in the pancreatic head area (i.e., a gastrinoma in a periduodenal lymph node was found at surgery) in a patient in whom the CT scan ( Figure 1 , top) and other conventional imaging methods were negative.
For localizing hepatic metastases in 24 patients with proven metastatic liver disease, SRS was the most sensitive of any localization method in detecting metastases in 92 percent (Table 1) , and it was equal to all conventional imaging methods combined. Other imaging studies were less sensitive with the exception of MRI (p = .12). Angiography detected hepatic metastases in 62 percent of patients but was less sensitive than SRS (p = .016) as was ultrasound which detected hepatic metastases in 46 percent (p = .001 vs. SRS), and CT, which detected hepatic metastases in 42 percent (p < .001 vs. SRS) of patients. Figure 2 (bottom) is an example of the high sensitivity of SRS in detecting hepatic metastases in a patient in whom the CT scan (Figure 2 , top) and other conventional imaging studies were negative.
Since we began using SRS at the NIH in June 1994, 31 patients underwent exploratory laparotomy for possible removal of the primary gastrinoma after the SRS and [15, 27, 28, 34, 56] . Figure 2 . CT scan and SRS of a patient with metastatic gastrinoma to the liver. This patient (NIH #1897238) is a 75-year-old female with histologically proven metastatic disease to the liver. The CT scan (top) shows no hepatic lesion. The SRS (bottom) shows two foci in the liver with one focus in the right liver lobe (arrow) and one focus in the left liver lobe (arrow). This patient illustrates the increased sensitivity of SRS over conventional imaging studies (CT, ultrasound, MRI) in detecting hepatic metastases and in demonstrating multiple metastases in different areas of the liver, which can influence determinations of possible resectability [34, 56, 57] . conventional imaging methods were performed. The results from 24 patients are shown in Table 2 . Twelve of these patients were from the 80 patients discussed above and reported recently [34] and 12 patients were more recent patients not included in the first 80 patients. Gastrinoma was found in all patients at surgery. A total of 40 gastrinomas were found: 13 gastrinomas in the duodenum, 3 in the pancreas and 24 in the lymph nodes. Although the sensitivity of SRS for localizing duodenal gastrinoma was low (38 percent) when compared to localizing pancreatic gastrinomas (100 percent) and gastrinoma in lymph nodes (88 percent), it was more sensitive than ultrasound, CT, MRI (0 to 8 percent) and equal to angiography or all conventional imaging methods combined (31 percent) ( Table 2 ). For duodenal and pancreatic tumors, SRS had equal sensitivity to that seen with all conventional imaging studies combined, but it was the more sensitive (88 percent) than a combination of all conventional imaging modalities in detecting gastrinomas in the lymph nodes ( Table 2 ).
RELATIONSHIP OF NIH RESULTS OF SRS SENSITIVITY COMPARED TO OTHER STUDIES IN PETS Applicability ofNIH results to other PETs
The results of our study likely have applicability to other less common PETs and carcinoid tumors for a number of reasons. Gastrinoma resembles all PETs with the exception of insulinoma in its biological behavior, growth pattern, histochemistry, rates of the occurrence of somatostatin receptors and malignant potential [2, 5, 6] . It resembles carcinoid tumors in the above characteristics, especially in the important areas of having a high density of somatostatin receptors, similar malignant potential and growth patterns [3, 13, 14, 36, 37] .
Comparison ofNIH results with SRS to those from other studies
The results of other studies in patients with Zollinger-Ellison syndrome and other PETs are compared with our study in Table 3 . The imaging studies were compared by the percentage of patients with a positive result and not on a lesion-by-lesion basis. For extrahepatic gastrinomas the sensitivity of SRS was 56 to 80 percent (Table 3) , which was more sensitive than other conventional imaging methods in the same study except CT (75 percent) in one series [39] . However, other studies in which SRS was not performed report higher sensitivities with CT and angiography than reported in most of the studies in Table  3 [1, 6, 40, 41] . For detecting metastatic gastrinomas, SRS has a 92 to 100 percent sensitivity, which was more sensitive than other imaging studies (42 to 76 percent) ( Table 3) . For series containing different PETs for the extrahepatic tumors, SRS was more sensitive than ultrasound, MRI and CT in two out of three studies (Table 3 , bottom). For identification of hepatic metastases in patients with various PETs, there is little data; however, in one study [16] , SRS was superior to CT, ultrasound or MRI (Table 3 , bottom). For insulinomas (Table 4 , top) the sensitivity of SRS for detecting extrahepatic tumors was as low as 20 percent to 46 percent, which was comparable with other imaging studies except angiography (63 percent) and CT (71 percent) in two series. For carcinoid tumors (Table  4 , bottom) there are not many studies that have compared SRS with other conventional imaging methods with different disease extents [18] . The data shown in Table 4 demonstrate that for carcinoid tumors the sensitivity of SRS and other conventional imaging methods are equal, in general, for extrahepatic and hepatic metastases [38] ; however, other studies reported that SRS was more sensitive in detecting distal metastases [18] .
COMPARISON OF THE RESULTS OF SRS AND EUS FOR LOCALIZING VARIOUS PETS
A number of recent studies have reported that endoscopic ultrasound (EUS) is a highly sensitive technique to localize PETs [15, 23, [25] [26] [27] [28] [29] [30] [31] [32] [33] . In Table 5 , results are shown from a comparison of SRS, EUS or CT in localizing various PETs from a number of studies, and the studies are stratified according to the type of tumor. For duodenal gastrinomas, there are little comparative data. Of the 11 duodenal gastrinomas in two studies, SRS recognized from 38 to 100 percent of duodenal tumors and EUS from 63 to 67 percent. These results suggest that both localization methods may miss a significant proportion of duodenal tumors. This possibility has been raised previously with EUS [42] and is consistent with our recent data in which SRS only localized 38 percent of duodenal gastrinomas (Table 2) . Two recent studies [15, 27] suggest in gastrinomas for identification of duodenal tumors or gastrinomas in lymph nodes that the combination of both EUS and SRS may be better than either alone. Pancreatic gastrinomas are generally larger than duodenal gastrinomas [43] and are well seen by EUS [25, 28, 29, 33] and by SRS [28] (Table 5 ). Recent studies demonstrate that EUS is much more sensitive than SRS [23, 28] or conventional imaging [29] [30] [31] [32] [33] for localizing pancreatic insulinomas. These data are consistent with results of recent studies that demonstrate that insulinomas frequently have a low density of high affinity octreotide receptors (sstr 2, 5) [28, 44] and, therefore, are not frequently seen on SRS (Table 4) . For all PETs of various types, the sensitivity of SRS was 52 percent in one study (Table 5) , EUS from 82 to 89 percent and CT scanning from 0 to 36 percent in the different studies.
The exact relative role of EUS or SRS in patients with PETs at present is controversial [42, 45] . This has occurred because there are few studies comparing EUS and SRS in a large number of patients. However, the results summarized in Table 5 suggest the following conclusions: First, for duodenal gastrinomas it is clear both studies miss a proportion of these tumors. It remains unclear the exact percentage identified by each modality, whether these studies identify sufficient numbers of duodenal gastrinomas that their use for this is justified and whether the combination is better than either alone. This is an important point because in recent surgical series duodenal gastrinomas are being found more frequently than pancreatic gastrinomas [6, 27, [46] [47] [48] . Second, for pancreatic gastrinomas, both EUS and SRS appear to identify 75-100 percent likely because these tumors are frequently large (i.e., >2 to 3 cm) [43] . It has, in fact, been recommended recently that EUS be routinely used in gastrinomas to exclude a pancreatic tumor [26] . For insulinomas EUS is clearly the procedure of choice. This conclusion is justified because these tumors are almost always intrapancreatic [49] [2, 5, [53] [54] [55] and thus, location of the primary may be either not difficult and can be easily accomplished with conventional imaging studies or is not indicated because it will not alter management.
In conclusion, our recent NIH study [34] combined with other studies on gastrinomas and other PETs (Tables 3 and 4) demonstrate that SRS has greater sensitivity than conventional imaging studies (ultrasound, CT, MRI, angiography) at localizing either the primary tumor or hepatic metastases. In patients with carcinoid tumors, SRS has equal or greater sensitivity to conventional imaging modalities in the two comparative studies reported. For insulinomas, EUS has the greatest sensitivity and should be the initial imaging study of choice. For the other PETs including gastrinomas, which are frequently malignant, SRS should be the initial localization modality because of its sensitivity and ability to examine the whole body at once. In the future, it will be important to establish whether EUS or SRS is best for localization of the primary tumor for patients without metastatic disease to the liver or whether they are complementary.
